Page last updated: 2024-08-21

chenodeoxycholic acid and Hepatorenal Syndrome

chenodeoxycholic acid has been researched along with Hepatorenal Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hou, MC; Hsieh, YC; Hsu, CF; Huang, CC; Huang, SF; Huang, YH; Lee, KC; Lee, TY; Li, TH; Lin, HC; Lin, MW; Liu, CW; Liu, HM; Tsai, YL; Yang, YY	1

Other Studies

1 other study(ies) available for chenodeoxycholic acid and Hepatorenal Syndrome

Article	Year
Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway. Clinical science (London, England : 1979), 2020, 08-14, Volume: 134, Issue:15 Topics: Animals; Apoptosis; Cell Line; Chenodeoxycholic Acid; Dinoprost; Drug Evaluation, Preclinical; Glutathione; Hepatorenal Syndrome; Liver Cirrhosis; Male; Oxidative Stress; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Thiobarbituric Acid Reactive Substances; Thromboxane A2; Vascular Resistance; Vasoconstriction	2020

Article

Year

Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway.

Clinical science (London, England : 1979), 2020, 08-14, Volume: 134, Issue:15

Topics: Animals; Apoptosis; Cell Line; Chenodeoxycholic Acid; Dinoprost; Drug Evaluation, Preclinical; Glutathione; Hepatorenal Syndrome; Liver Cirrhosis; Male; Oxidative Stress; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Thiobarbituric Acid Reactive Substances; Thromboxane A2; Vascular Resistance; Vasoconstriction

2020